Why the study?
Most current AMI clinical practice guidelines are based on studies in non-Asian populations from the pre-PCI era.
This expert consensus document provides tailored recommendations for the pharmacologic management of acute myocardial infarction in Korean patients, addressing potential ethnic differences and regional clinical practices not fully covered by Western guidelines.
May inform ethnicity-tailored AMI pharmacotherapy in Koreans; extends guidelines but leaves validation to prospective trials.
Clinical practice guidelines published by the European Society of Cardiology and the American College of Cardiology/American Heart Association summarize the available evidence and provide recommendations for health professionals to enable appropriate clinical decisions and improve clinical outcomes for patients with acute myocardial infarction (AMI). However, most current guidelines are based on studies in non-Asian populations in the pre-percutaneous coronary intervention (PCI) era. The Korea Acute Myocardial Infarction Registry is the first nationwide registry to document many aspects of AMI from baseline characteristics to treatment strategies. There are well-organized ongoing and published randomized control trials especially for antiplatelet therapy among Korean patients with AMI. Here, members of the Task Force of the Korean Society of Myocardial Infarction review recent published studies during the current PCI era, and have summarized the expert consensus for the pharmacotherapy of AMI.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2020) conducted a review in Acute Myocardial Infarction. Pharmacotherapy was evaluated. This expert consensus document provides tailored recommendations for the pharmacotherapy of acute myocardial infarction in Korean patients, addressing ethnic differences in pharmacologic responses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: